Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9446147 | 0.79 | CYP3A4 (0.44) | ALDH1A1ALOX15HSD17B10HPGDTDP1 | |
| SCHEMBL23226967 | 0.76 | CYP3A4 (0.33) | ALDH1A1HPGDTDP1LMNACYP3A4 | |
| SCHEMBL24945815 | 0.76 | DAO (0.35) | ALDH1A1ALOX15HSD17B10HPGDTDP1 | |
| SCHEMBL26501860 | 0.76 | CYP3A4 (0.34) | ALDH1A1ALOX15HSD17B10HPGDTDP1 | |
| SCHEMBL24806431 | 0.75 | CYP3A4 (0.52) | ALDH1A1ALOX15HSD17B10HPGDTDP1 | |
| SCHEMBL7037132 | 0.75 | ALDH1A1 (0.45) | ALDH1A1ALOX15HSD17B10HPGDTDP1 | |
| SCHEMBL24946313 | 0.74 | CSNK2A2 (0.38) | ALDH1A1ALOX15HSD17B10HPGDTDP1 | |
| SCHEMBL29295813 | 0.74 | TSHR (0.39) | ALDH1A1ALOX15HSD17B10HPGDTDP1 | |
| SCHEMBL24945808 | 0.74 | ESR1 (0.39) | ALDH1A1ALOX15HSD17B10HPGDTDP1 | |
| SCHEMBL26503324 | 0.73 | LMNA (0.34) | HPGDLMNATYRHTTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNK3 | ALDH1A1 1717/4885ALOX15 4643/4885HSD17B10 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.